Cardiovascular effects of anti-obesity medications: the perils and promise DOI Creative Commons
Haoyi Zheng

Cardiology Plus, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Anti-obesity medications have gone through a tumultuous course of approvals and withdrawals, often triggered by serious cardiovascular complications. Early agents, including amphetamines fenfluramine–phentermine, were once widely used but ultimately banned or voluntarily withdrawn due to Sibutramine followed similar trajectory when clinical trials revealed increased event rates, prompting its market withdrawal. Lorcaserin, initially promising for weight management without significant risks, was after postmarketing surveillance potential link cancer incidence. Although more recent medications, orlistat, phentermine–topiramate, naltrexone–bupropion, remain available, their cardiometabolic benefits are modest, long-term outcome data inconclusive still lacking. The emergence glucagon-like peptide 1 (GLP-1) receptor agonists co-agonists has transformed obesity management. Liraglutide, semaglutide, tirzepatide, originally developed type 2 diabetes, demonstrated substantial sustained loss along with notable improvements in markers. In high-risk populations, randomized liraglutide semaglutide also shown reductions major adverse events. Moreover, tirzepatide exhibited patients heart failure preserved ejection fraction obesity. Overall, GLP-1 hold promise, however, questions regarding safety effects broader populations. history approval withdrawal anti-obesity underscores the importance surveillance. As evidence continues accumulate, balance between efficacy will guide optimal use both risk reduction.

Language: Английский

Preoperative weight loss by noninvasive approach in patients with obesity scheduled for bariatric and metabolic surgery: an update narrative review of indications and results available until 2024 DOI Creative Commons

Ilenia Grandone,

Monica Nannipieri, Caterina Conte

et al.

Updates in Surgery, Journal Year: 2025, Volume and Issue: unknown

Published: April 12, 2025

Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity its metabolic complications. Currently, MBSs are performed laparoscopically. However, high weight associated with an enlarged liver (especially left lobe section, LLLS) may complicate technical aspects of this surgery. Therefore, before MBS, moderate preoperative loss (PreopWL), reduction in LLLS desirable. Moreover, studies inconclusive regarding which best approach to apply. This narrative review aimed describe current scientific evidence on effect a noninvasive approach, such as dietary or pharmacotherapy space-occupying devices PreopWL, peri-operative complications, hospital length stay, post-operative complications patients scheduled MBS. We conducted literature search screening relevant publications from January 2010 June 2024. found that PreopWL MBS helpful both surgeons, it leads various benefits, decrease body size, lower risk intra- shorter times, reduced stays. In context, concerning approaches, several protocols have been introduced over time, among very low-calorie diets low energy ketogenic therapy widely prescribed; however, larger randomized-controlled trials (RCTs) well-defined necessary make definitive conclusions. Obesity management medications, lipase inhibitor orlistat, phentermine/topiramate, naltrexone/bupropion, glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide semaglutide, novel dual glucose dependent insulinotropic peptide (GIP)/GLP-1 agonist tirzepatide, has shown be promoting MBS; larger, well-designed RCTs needed establish optimal assess their true benefits Space-occupying swallowable intragastric balloon hydrogel capsules, represent promising tools but further research essential confirm role.

Language: Английский

Citations

0
Comparing Clinical Practice Habits among Obesity Medicine Physicians by Patient, Physician and Clinic Factors DOI Creative Commons
Selvi Rajagopal,

Edmond P. Wickham,

Tirissa J. Reid

et al.

Obesity Pillars, Journal Year: 2025, Volume and Issue: 13, P. 100157 - 100157

Published: Jan. 7, 2025

While clinical practice habits vary by patient, physician and clinic factors in primary care, limited research has examined whether differences exist obesity medicine. Our objective was to compare such among medicine physicians certified the American Board of Obesity Medicine (ABOM). We conducted secondary analyses cross-sectional data from 2023 ABOM Practice Analysis Validation Survey. included three - prescribing anti-obesity medications (AOMs), off-label for weight reduction, hours (4-20 h/week versus >20 h/week). patient (patient population), (primary medical specialty, years experience) (practice setting, geographic catchment, accepts insurance care). bivariate using Χ2 tests. Among 565 ABOM-certified physicians, 71.5 % had specialties within care 9.2 predominantly treated children/adolescents with obesity. Overall, 97.5 prescribed AOMs 85.1 reduction. Fewer who compared no or treatment children (88.5 98.4 98.5 %, respectively; p < 0.001). 41.4 reported practicing h/week, which more likely occur as experience increased (i.e., 21.9 ​% 1-2 58.5 10+ years; ​< ​0.001). No significant occurred accepting insurance. findings may suggest that have consistent medication practices regardless factors, be particularly important patients seeking pharmacologic treatment. Most treat prescribe medications. These current rates are relatively higher than prior pediatric might help support access patients.

Language: Английский

Citations

0
Solving the Mystery of the Obesity Paradox: A Call for Better Data? DOI
Nicole Siparsky

Critical Care Medicine, Journal Year: 2025, Volume and Issue: 53(3), P. e730 - e732

Published: Jan. 8, 2025

Rush University Medical Center, Chicago, IL. Dr. Siparsky received funding from Wolters Kluwer (UpToDate).

Language: Английский

Citations

0
Development and characterization of a chicory extract fermented by Akkermansia muciniphila: An in vitro study on its potential to modulate obesity-related inflammation DOI Creative Commons
Arthur Chervet, Reine Nehmé,

C. Defois-Fraysse

et al.

Current Research in Food Science, Journal Year: 2025, Volume and Issue: 10, P. 100974 - 100974

Published: Jan. 1, 2025

de niveau recherche, publiés ou non, émanant des établissements d'enseignement et recherche français étrangers, laboratoires publics privés.

Citations

0
Hawthorn carbon dots: a novel therapeutic agent for modulating body weight and hepatic lipid profiles in high-fat diet-fed mice DOI
Shuai Lin, Y. H. Zheng, Yi Xu

et al.

Nanoscale, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Synthesis of HCD (A) and intervention on obesity in high-fat diet mice (B).

Language: Английский

Citations

0
Real-life data about obesity management DOI Creative Commons
Jacques Devière

Endoscopy International Open, Journal Year: 2025, Volume and Issue: 13(CP)

Published: Jan. 29, 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as original work properly cited. (https://creativecommons.org/licenses/by/4.0/).

Language: Английский

Citations

0
Hesperetin mitigates adipose tissue inflammation to improve obesity-associated metabolic health DOI
Qiu Chen, Wenjun Chen, Beining Zhang

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 149, P. 114211 - 114211

Published: Feb. 9, 2025

Language: Английский

Citations

0
Enzymatic Hydrolysates of κ-Carrageenan by κ-Carrageenase-Based Magnetic Cross-Linked Nanoflowers Confers Pancreatic Lipase Inhibition Activity DOI

Chun‐Hua Zhu,

Tao Hong,

Mingjing Mou

et al.

Journal of Agricultural and Food Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 13, 2025

The immobilized κ-carrageenase MCNF was developed by synergistic integration of κ-carrageenase, calcium phosphate crystals, and magnetic nanoparticles. outperformed free in terms optimal temperature, thermostability (45–55 °C), stability (pH 6.0 12.0), storage stability. Furthermore, extremely reusable easy to separate from the reaction system. MCNF's enzymatic breakdown κ-carrageenan resulted a tetrasaccharide that competitively inhibited pancreatic lipase (PL). Fluorescence titration experiments showed altered microenvironment PL causing static bursting its intrinsic fluorescence. circular dichroism experiment demonstrated adding reduced α-helix content increased β-sheet PL's secondary structure. Molecular docking dynamics simulation research suggested could form stable complex with PL, entering hydrophobic cavity occupying active site, reducing catalytic activity. κ-Carrageenan inhibit making it promising therapeutic agent for obesity prevention treatment.

Language: Английский

Citations

0
Medical Management of Obesity: Current Trends and Future Perspectives DOI
Andrés Calderón,

Maria Aguilera Astudillo,

Alexsandra P. Rojas

et al.

Methodist DeBakey Cardiovascular Journal, Journal Year: 2025, Volume and Issue: 21(2), P. 62 - 73

Published: Jan. 1, 2025

Obesity and overweight have become increasingly significant conditions, affecting more than 70% of the adult population in United States. These conditions are caused by a combination factors, including genetic, behavioral, environmental, medical influences. is major risk factor for cardiovascular metabolic diseases. A comprehensive treatment plan individuals with obesity must recognize chronic nature condition offer strategies weight reduction long-term cardiometabolic benefits. Over past several decades, multiple therapeutic options been implemented to address loss, appetite regulation, caloric expenditure, goal reducing burden improving outcomes. Pharmacological has focused primarily on central regulation food intake behavior. The introduction incretin agonists ushered new era health, multitargeted mechanism that achieves glycemic control, decreased mortality, other This review explores current pharmacological future treatment.

Language: Английский

Citations

0
One Size Does Not Fit All: Special Considerations for Behavioral Health Providers Treating Patients Using GLP-1RA Medications for Obesity DOI
Noreen A. Reilly-Harrington, Susan Himes, Jennifer Lauretti-Robbins

et al.

Cognitive and Behavioral Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0